Neoplasia/BPH

	The combination of atezolizumab and BCG in high-risk non-muscle invasive bladder cancer: results of the phase Ib/II BladderGATE clinical trial. Oncologist Guerrero-Ramos F, Gómez-Cañizo C, Rodríguez-Izquierdo M, Hernández-Arroyo M, Rodríguez-Antolín A, de Velasco G, Ponce-Aix S, Paramio JM, Suárez-Cabrera C, Rubio C, Morales L, García-Martínez V, Dueñas M, Castellano D. PMID: 42103978 [PubMed - as supplied by publisher]
	PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers. Eur Urol Oncol Shadbahr T, Pylväläinen J, Eineluoto J, Moro A, Kerro O, Kenttämies A, Czeizler E, Murtola TJ, Kim-Ollila HJ, Puech P, Olivier J, Villers A, Peltonen J, Nykter M, Tang J, Mirtti T, Laajala TD, Rannikko AS. PMID: 42103551 [PubMed - as supplied by publisher]
	Renal presentation of diffuse large B-cell lymphoma emerging after pre-existing IgG4-related disease and monoclonal gammopathy of undetermined significance. BMJ Case Rep Jlasi A, Gomez A, Deng X. PMID: 42103345 [PubMed - indexed for MEDLINE]
	Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer. Rev Esp Patol González-Peramato P, García-Fernández E, Jambrina A, Salinas JF, Hernández-Losa J, Linares-Espinós E, Rojo F, Mateo J, Olmos D. PMID: 42102633 [PubMed - as supplied by publisher]
	Pathological assessment of morcellated tissue after ERBT: insights from a two-round Delphi survey. World J Urol Ventura Y, Morozov A, Chan R, Combat Faria Tavares M, Teoh JY, Compérat E, Cheng L, Fridman E, Lerner J, Baraban E, Yakimov M, Lokshin K, Lifshitz D, Golan S, Gauhar V, Herrmann TRW, Shariat S, Enikeev D. PMID: 42101641 [PubMed - indexed for MEDLINE]
	A multicenter study of automatic segmentation-based multimodal fusion integrating radiomics, deep learning, and clinical parameters for prostate cancer detection. Abdom Radiol (NY) Ding N, Jin L, Yin S, Ji Y, Wang X, Li M. PMID: 42101624 [PubMed - as supplied by publisher]
	The Impact of Specialist Palliative Care on the Utilization of Health Care Services at the End of Life Among Patients With Prostate Cancer: A Nationwide Register-based Study. Eur Urol Open Sci Carpén TP, Nåhls NA, Nuutinen MSJ, Saarto TH. PMID: 42100443 [PubMed]
	Abdominal disseminated lesions following surgery for a testicular mucinous cystic neoplasm initially diagnosed as mucinous cystadenoma: a case report and literature review. Front Oncol Yang J, Li W, Wang J, Li J. PMID: 42100427 [PubMed]
	Aerobic glycolysis in bladder cancer: research advances and targeted therapy potential. Front Oncol Pan M, Tao T, Kong D, Gong H. PMID: 42100416 [PubMed]
	Mechanistic insights and molecular therapy for neuroendocrine prostate cancer. Front Oncol Niu Y, Zhang S, Zhang S, Tao J, Zhu Y. PMID: 42100391 [PubMed]
	Translational insights into miR-126 and miR-423: biomarkers and therapeutic targets in cancer, cardiovascular, metabolic and kidney diseases. Front Mol Biosci Rodzo. PMID: 42100367 [PubMed]
	Solitary fibrous tumor: A contender in the differential diagnosis of a renal mass. Indian J Urol Kareem Z. PMID: 42099838 [PubMed]
	Machine learning-based integration of systemic immune-inflammation and nutritional signatures for predicting disease-free survival in upper tract urothelial carcinoma: a multicenter study. Front Immunol Peng X, Xiao B, Yuan Z, Xv Y, Xiao M, Shi W. PMID: 42099622 [PubMed - indexed for MEDLINE]
	Gut microbiota and its metabolites: Key factors of drug resistance in the treatment of advanced prostate cancer (Review). Mol Med Rep Song J, Cui H, Yang P, Xu Y, Liu Y, Zhang G, Liu Y, Tian A, Che J, Sun H, Zhang Z. PMID: 42099232 [PubMed - indexed for MEDLINE]
	FOXA1 is a highly sensitive diagnostic marker for prostate cancer including small cell carcinoma of the prostate. Histopathology Zhao J, Yao J, Hosseini H, Baraban E, Lin R, Guo CC, Huo L, Lu W, Khan K, Wang S, Soto LMS, Ding Q. PMID: 42098986 [PubMed - as supplied by publisher]
	Prostate cancer therapeutic strategies decided based on in-bore MRI-targeted prostate biopsies alone, or in combination with TRUS-guided biopsies. World J Urol Schull A, Gachet J, Tavolaro S, Santy A, Bornet G. PMID: 42098380 [PubMed - indexed for MEDLINE]
	Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial. Nat Commun Sharma P, Krainer M, Saad F, Castellano D, Bedke J, Kwiatkowski M, Patnaik A, Procopio G, Wiechno P, Kochuparambil S, Thomas C, Arranz Arija JÁ, McCune SL, Hansen S, Daugaard G, Delgado Mingorance JI, Kukard C, Subudhi SK, Basu S, Jindal S, Siddiqui BA, Lako A, Gupta S, Fedorov V, Amin NP, Campos A, Wang Y, David JM, Pachynski RK. PMID: 42098105 [PubMed - as supplied by publisher]
	Druggable Genome-Wide Mendelian Randomization Identifies Therapeutic Targets and DNA Methylation-Mediated Regulation in Urological Malignancies. Technol Cancer Res Treat Li T, Wei Q. PMID: 42098041 [PubMed - indexed for MEDLINE]
	Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial. BMJ Open Cooper S, Alexander S, Breitkreutz D, Casey F, Christodouleas J, Dassen MG, Dell'acqua V, Dunlop A, Herbert T, Kolias P, Mitchell A, Pos FJ, Westley R, Tree AC, Van Der Heide UA, Vesprini D. PMID: 42097645 [PubMed - indexed for MEDLINE]
	Outdoor air pollution and prostate cancer risk in the NIH-AARP diet and health study. J Natl Cancer Inst Post LM, Hurwitz L, Fisher JA, Kaufman JD, Koutros S, Jones RR. PMID: 42097289 [PubMed - as supplied by publisher]

Articles 1 - 20 / 187672

Page 1 of 9384



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy